HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
批准号:
6519770
负责人:
RICHARD B KIM
金额:
$17.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-07-01 至 2003-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The overall objective of this application is to further our understanding
of the role of carrier-mediated processes responsible for the uptake of
xenobiotics from the systemic circulation into the liver -a critical first
step in their hepatic elimination. A number of human hepatic
basolateral membrane transporters have recently been cloned and
functionally characterized with respect to the transport of endogenous
compounds such as bile acids. We have cloned two novel human
hepatic drug transporters with sequence homologies to the rat organic
cation transporter (rOCT1), and the human organic anion transporter
(hOATP). In addition, we have identified a mutation (Phe83-
>Ser83)in the human hepatic sodium-dependent bile acid transporter,
hNTCP, resulting from a single T->C substitution, that has a marked
reduction in its transport activity. It is our hypothesis that these
transport systems recognize a variety of drugs in clinical use, and that
variability in function or activity has important implications in terms of
drug elimination and therapy. Therefore, studies are proposed to test
specific hypothesis through functional expression of individual
transporters. The proposed studies in Specific Aim 1 will test the
hypothesis that our newly cloned transporters, hOATP2 and hNLT,
represent the biochemically characterized multispecific bile acid
transporter, and a liver specific organic cation transporter, respectively.
We will also define the transport kinetics of the mutant hNTCP
transporter to assess whether this mutation alters substrate affinity.
Additionally, the hypothesis will be tested that transport by hNTCP
plays a pivotal role in the therapeutic response to tauroursodeoxycholic
acid (in cholestatic liver disease) and to octreotide (in cancer
chemotherapy). Specific Aim 2 focusses on site-directed mutagenesis
and homologous chimera construction methods that will be used to
better understand and identify key domains conferring transporter
activity and substrate specificity. These studies will provide important
insights regarding human hepatic drug transport systems, and enhance
our understanding of the role of such processes in drug disposition.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INTESTINAL AND HEPATIC DRUG TRANSPORTERS
-
批准号:6482470
-
项目类别:
-
资助金额:$14.08万
-
财政年份:2001
-
负责人:RICHARD B KIM
-
依托单位:
INTESTINAL AND HEPATIC DRUG TRANSPORTERS
-
批准号:6325865
-
项目类别:
-
资助金额:$26.76万
-
财政年份:2000
-
负责人:RICHARD B KIM
-
依托单位:
INTESTINAL AND HEPATIC DRUG TRANSPORTERS
-
批准号:6107501
-
项目类别:
-
资助金额:$26.76万
-
财政年份:1999
-
负责人:RICHARD B KIM
-
依托单位:
HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
-
批准号:2378344
-
项目类别:
-
资助金额:$16.25万
-
财政年份:1998
-
负责人:RICHARD B KIM
-
依托单位:
HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
-
批准号:6019193
-
项目类别:
-
资助金额:$10.65万
-
财政年份:1998
-
负责人:RICHARD B KIM
-
依托单位:
Hepatic Drug Transporters in Drug Disposition
-
批准号:6909064
-
项目类别:
-
资助金额:$44.9万
-
财政年份:1998
-
负责人:RICHARD B KIM
-
依托单位:
HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
-
批准号:6180909
-
项目类别:
-
资助金额:$16.91万
-
财政年份:1998
-
负责人:RICHARD B KIM
-
依托单位:
HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
-
批准号:6386552
-
项目类别:
-
资助金额:$17.41万
-
财政年份:1998
-
负责人:RICHARD B KIM
-
依托单位:
Hepatic Drug Transporters in Drug Disposition
-
批准号:6685485
-
项目类别:
-
资助金额:$38.52万
-
财政年份:1998
-
负责人:RICHARD B KIM
-
依托单位:
INTESTINAL AND HEPATIC DRUG TRANSPORTERS
-
批准号:6271743
-
项目类别:
-
资助金额:$26.11万
-
财政年份:1998
-
负责人:RICHARD B KIM
-
依托单位:
Hepatic Drug Transporters in Drug Disposition
-
批准号:6766010
-
项目类别:
-
资助金额:$39.67万
-
财政年份:1998
-
负责人:RICHARD B KIM
-
依托单位:
INTESTINAL AND HEPATIC DRUG TRANSPORTERS
-
批准号:6240424
-
项目类别:
-
资助金额:$28.41万
-
财政年份:1997
-
负责人:RICHARD B KIM
-
依托单位:
HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
-
批准号:2659252
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1997
-
负责人:RICHARD B KIM
-
依托单位:
海外基金